Generated: December 16, 2017
DrugPatentWatch Database Preview
Details for Patent: 9,301,932
« Back to Dashboard
Which drugs does patent 9,301,932 protect, and when does it expire?
Summary for Patent: 9,301,932
|Title:||Liquid pharmaceutical composition comprising nitisinone|
|Abstract:|| The invention concerns a liquid pharmaceutical formulation suitable for oral administration, comprising a suspension of an effective amount of micronized 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (nitisinone); and citric acid buffer having a pH in the range of 2.5 to 3.5. The formulation is useful in the treatment of disorders and diseases in which inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) is desirable, e.g. in hereditary tyrosinaemia type I.|
|Inventor(s):|| Svensson; Lennart (Solna, SE), Siden; Hans (Sollentuna, SE) |
|Assignee:|| SWEDISH ORPHAN BIOVITRUM INTERNATIONAL AB (Stockholm, SE) |
Patent Claim Types:|
see list of patent claims
|Formulation; Compound; Dosage form; Use; |
||Patented / Exclusive Use
|Swedish Orphan||ORFADIN||nitisinone||SUSPENSION;ORAL||206356-001||Apr 22, 2016||RX||Yes||Yes||► Subscribe||► Subscribe||Y||TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANIE||► Subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
Foreign Priority and PCT Information for Patent: 9,301,932
|Foriegn Application Priority Data|
||Foreign Patent Number
||Foreign Patent Date
|Sweden||1150585||Jun 23, 2011|
|PCT Filed||June 20, 2012||PCT Application Number:||PCT/SE2012/050681|
|PCT Publication Date:||December 27, 2012||PCT Publication Number:||
International Patent Family for Patent: 9,301,932
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.